Virax Biolabs Group (Virax Biolabs Group) Receivables Turnover

: 0.00 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Virax Biolabs Group's Revenue for the six months ended in Sep. 2023 was $0.08 Mil. Virax Biolabs Group's average Accounts Receivable for the six months ended in Sep. 2023 was $0.00 Mil.

Virax Biolabs Group Receivables Turnover Historical Data

The historical data trend for Virax Biolabs Group's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Receivables Turnover

124.00

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Receivables Turnover				-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Virax Biolabs Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group Receivables Turnover Distribution

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Receivables Turnover falls into.

Virax Biolabs Group Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Virax Biolabs Group's Receivables Turnover for the fiscal year that ended in Mar. 2023 is calculated as

	Receivables Turnover (A: Mar. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Mar. 2023 )	/ (	(Accounts Receivable (A: Mar. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )
=	0.009	/ (	(0	+	0)	/	1 )
=	0.009	/	0
=	N/A

Virax Biolabs Group's Receivables Turnover for the quarter that ended in Sep. 2023 is calculated as

	Receivables Turnover (Q: Sep. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2023 )	/ (	(Accounts Receivable (Q: Mar. 2023 )	+	Accounts Receivable (Q: Sep. 2023 ))	/	count )
=	0.077	/ (	(0	+	0)	/	1 )
=	0.077	/	0
=	N/A

Virax Biolabs Group (NAS:VRAX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Virax Biolabs Group Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.